Long-term benefits of darifenacin treatment for patient quality of life: Results from a 2-year extension study

Neurourology and Urodynamics

Volumn 27, Issue 6, 2008, Pages 540-547

  Dwyer, Peter ^a   Kelleher, Con ^b   Young, Jay ^c   Haab, François ^d   Lheritier, Karine ^e   Ariely, Rinat ^e   Ebinger, Ursula ^e  

^a MERCY HOSPITAL FOR WOMEN   (Australia)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c Orange Country Urology Associates   (United States)

^d HÔPITAL TENON   (France)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Antimuscarinic drug; Clinical trial; Darifenacin; King's Health Questionnaire; Long term; Overactive bladder

Indexed keywords

DARIFENACIN; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN RELATION; KING HEALTH QUESTIONNAIRE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; OVERACTIVE BLADDER; PATIENT SATISFACTION; PHYSICAL ACTIVITY; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SLEEP; SOCIAL ASPECT; TREATMENT OUTCOME; XEROSTOMIA;

ADULT; AGED; AGED, 80 AND OVER; AUSTRALIA; BENZOFURANS; DOUBLE-BLIND METHOD; EUROPE; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PATIENT SATISFACTION; PYRROLIDINES; QUALITY OF LIFE; QUESTIONNAIRES; RECEPTOR, MUSCARINIC M3; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; URINARY BLADDER, OVERACTIVE;

EID: 50849086091     PISSN: 07332467     EISSN: 15206777     Source Type: Journal    
DOI: 10.1002/nau.20620     Document Type: Article

References (26)

1. Abrams P, Cardozo L, Fall M, et al. The standardisatjon of terminology of lower urinary tract function: Report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:167-78.
2. Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: Results of the EPIC study. Eur Urol 2006;50:1306-14.
3. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalenre and burden of overactive bladder in the United States. World J Urol 2003;20:327-36.
4. Abrams P, Kelleher CJ, Kerr LA, et al. Overactive bladder significantly affects quality of life. Am J Manag Care 2000;6:S580-90.
5. Kelleher CJ. Economic and social impact of OAB. Eur Urol 2002;46:11-6.
6. Kelleher C, Westphalen T, Ellsworth P. The emotional burden of overactive bladder (OAB) symptoms on sufferers. Eur Urol Suppl 2005;4:59 (Abstract 228).
7. Abrams P, Artibani W, Gajewski JB, et al. Assessment of treatment outcomes in patients with overactive bladder: Importance of objective and subjective measures. Urology 2006;68:17-28.
8. Andersson K-E. Antimuscarinics for treatment of overactive bladder. Lancet Neurol 2004;3:46-53.
9. 3 selective receptor antagonist, in the treatment of overactive bladder. BJU Int 2005;95:993-1001.
10. Zinner N. Darifenacin: A muscarinic M3-selective receptor antagonist for the treatment of overactive bladder. Expert Opin Pharmacother 2007;8:511-23.
11. Abrams P, Kelleher C, Huels J, et al. Clinical relevance of health-related quality of life outcomes with darifenacin. BJU Int 2008; [Epub ahead of print]
12. Reese PR, Pleil AM, Okano GJ, et al. Multinational study of reliability and validity of the King's Health Questionnaire in patients with overactive bladder. Qual Life Res 2003;12:427-42.
13. Haab F, Corcos J, Siami P, et al. Long-term treatment with darifenacin for overactive bladder: Results of a 2-year, open-label extension study. BJU Int 2006;98:1025-32.
14. Hill S, Elhilali M, Millard R, et al. Long-term darifenacin treatment for overactive bladder in patients aged 65 years and older: Analysis of results from a 2-year, open-label extension study. Curr Med Res Opin 2007;23:2697-704.
15. Zellner M, Lheritier K, Kawakami FT, et al. Efficacy, tolerability and safety of long-term darifenacin treatment in men with overactive bladder: A 2-year, open-label, extension study (abstr.). Abstract presented at the World Congress of Men's Health and Gender 2005; Vienna, Austria 30 September-1 October 2005.
16. Steers W, Corcos J, Foote J, et al. An investigation of dose titration with darifenacin, an M3-selective receptor antagonist. BJU Int 2005;95:580-6.
17. Haab F, Stewart I, Dwyer P. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol 2004;45:420-9.
18. Abrams P, Avery K, Gardener N, et al. The International Consultation on Incontinence Modular Questionnaire: www.iciq.net. J Urol 2006;175:1063-6.
19. Kelleher CJ, Pleil AM, Reese PR, et al. How much is enough and who says so? The case of the King's Health Questionnaire and overactive bladder. Br J Obstet Gynaecol 2004;111:605-12.
20. Kelleher CJ, Cardozo L, Khullar V, et al. A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol 1997;104: 1374-479.
21. Liberman IN, Hunt TL, Stewart WF, et al. Health-related quality of life among adults with symptoms of overactive bladder: Results from a US community-based survey. Urology 2001;57:1044-50.
22. Donovan A, Bosch R, Gotoh M, et al. Symptom and Quality of Life assessment. In: Abrams P, Cardozo L, Khoury S, Wein A, editors. Incontinence. Book 1. Basics and evaluation. International Continence Society, Bristol, UK; 2005.
23. Khullar V, Chapple C, Gabriel Z, et al. The effects of antimuscarinics on health-related quality of life in overactive bladder: A systematic review and meta-analysis. Urology 2006;68:38-48.
24. Payne CK, Kelleher C. Redefining response in overactive bladder syndrome. BJU Int 2007;99:101-6.
25. Shamliyan TA, Kane RL, Wyman J, et al. Systematic review: Randomized. controlled trials of nonsurgical treatments for urinary incontinence in women. Ann Intern Med 2008.
26. Bolge SC, McDonnell DD, Chen A, et al. Patient satisfaction with extended release tolterodine or oxybutynin in overactive bladder. Curr Med Res Opin 2007;23:1903-12.